Collegium Pharmaceutical, Inc.

NasdaqGS:COLL 주식 보고서

시가총액: US$1.1b

Collegium Pharmaceutical 관리

관리 기준 확인 4/4

Collegium Pharmaceutical CEO는 Mike Heffernan, Jan2002 에 임명되었습니다 의 임기는 22.83 년입니다. 는 $ 916.90K 가치에 해당하는 회사 주식의 0.087% 직접 소유합니다. 916.90K. 경영진과 이사회의 평균 재임 기간은 각각 5.2 년과 10.8 년입니다.

주요 정보

Mike Heffernan

최고 경영자

US$330.6k

총 보상

CEO 급여 비율n/a
CEO 임기22.8yrs
CEO 소유권0.09%
경영진 평균 재임 기간5.2yrs
이사회 평균 재임 기간10.8yrs

최근 관리 업데이트

Recent updates

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Oct 28
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

CEO 보상 분석

Mike Heffernan 의 보수는 Collegium Pharmaceutical 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

US$100m

Mar 31 2024n/an/a

US$93m

Dec 31 2023US$331kn/a

US$48m

Sep 30 2023n/an/a

US$9m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$334kn/a

-US$25m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

US$43m

Dec 31 2021US$353kn/a

US$72m

Sep 30 2021n/an/a

US$104m

Jun 30 2021n/an/a

US$107m

Mar 31 2021n/an/a

US$42m

Dec 31 2020US$304kn/a

US$27m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$198k

Mar 31 2020n/an/a

-US$13m

Dec 31 2019US$251kn/a

-US$23m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$22m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$5mUS$317k

-US$39m

Sep 30 2018n/an/a

-US$66m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$70m

Dec 31 2017US$3mUS$547k

-US$75m

보상 대 시장: Mike 의 총 보상 ($USD 330.61K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.23M ).

보상과 수익: Mike 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Mike Heffernan (60 yo)

22.8yrs

테뉴어

US$330,614

보상

Mr. Michael Thomas Heffernan, also known as Mike, B.S. Pharm, R.Ph. serve as Independent Director at K36 Therapeutics, Inc. He serves as Lead Independent Director at Biohaven Ltd. since September 2022.Mr....

리더십 팀

이름위치테뉴어보상소유권
Michael Heffernan
Co-Founder22.8yrsUS$330.61k0.087%
$ 916.9k
Colleen Tupper
Executive VP & CFO3.5yrsUS$2.73m0.061%
$ 645.0k
Shirley Kuhlmann
Executive VP6.7yrsUS$2.87m0%
$ 0
Scott Dreyer
Executive VP & Chief Commercial Officer6.3yrsUS$2.61m0%
$ 0
Thomas Smith
Executive VP & Chief Medical Officer2.7yrsUS$2.04m0%
$ 0
Christopher James
Vice President of Investor Relationsno data데이터 없음데이터 없음
Bart Dunn
Executive Vice President of Strategy & Corporate Development5.2yrs데이터 없음데이터 없음
Scott Sudduth
Head of Technical Operations3.1yrs데이터 없음데이터 없음

5.2yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: COLL 의 관리팀은 노련하고 경험 (평균 재직 기간 5.2 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Michael Heffernan
Co-Founder21.1yrsUS$330.61k0.087%
$ 916.9k
John Freund
Independent Director10.8yrsUS$298.61k0.22%
$ 2.3m
Garen Bohlin
Independent Director9.8yrsUS$299.61k0.0073%
$ 76.9k
Gino Santini
Lead Independent Director12.3yrsUS$322.61k0.079%
$ 832.5k
Bill McCarberg
Scientific Advisorno data데이터 없음데이터 없음
Nathaniel Katz
Scientific Advisorno data데이터 없음데이터 없음
Robert Dworkin
Scientific Advisorno data데이터 없음데이터 없음
Lynn Webster
Scientific Advisorno data데이터 없음데이터 없음
John Fallon
Independent Director8.4yrsUS$289.61k0.12%
$ 1.2m
Cynthia McCormick
Scientific Advisorno data데이터 없음데이터 없음
Richard Rauck
Scientific Advisorno data데이터 없음데이터 없음
Charles Argoff
Scientific Advisorno data데이터 없음데이터 없음

10.8yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: COLL 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.8 년).